CN112316020A - Application of compound Fengshining preparation in treating osteoarthritis - Google Patents
Application of compound Fengshining preparation in treating osteoarthritis Download PDFInfo
- Publication number
- CN112316020A CN112316020A CN202011316500.8A CN202011316500A CN112316020A CN 112316020 A CN112316020 A CN 112316020A CN 202011316500 A CN202011316500 A CN 202011316500A CN 112316020 A CN112316020 A CN 112316020A
- Authority
- CN
- China
- Prior art keywords
- parts
- compound
- medicament
- treating osteoarthritis
- feng shi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a new application of compound rheumatism medicament in preparing medicament for treating osteoarthritis, wherein the compound rheumatism medicament comprises the following medicinal materials in parts by weight: 1.5-4.5 parts of shinyleaf pricklyash root, 1.5-4.5 parts of stauntonvine, 1-3 parts of tinospora sinensis, 1-3 parts of climbing fern rhizome, 0.5-1.5 parts of clematis root and 0.5-1.5 parts of chicken bone essence. The application provides a new application of the existing compound Fengshining in treating osteoarthritis, and provides a new medicine selection for treating osteoarthritis.
Description
Technical Field
The invention discloses a new application of a conventional compound rheumatism preparation, in particular to a new application of a conventional compound rheumatism preparation in treating osteoarthritis.
Background
Osteoarthritis is a degenerative disease, which is caused by degenerative damage of articular cartilage and reactive hyperplasia of articular margin and subchondral bone due to aging, obesity, strain, trauma, congenital abnormality of joints, joint deformity and other factors, and is also called osteoarthropathy, degenerative arthritis, senile arthritis, hypertrophic arthritis, etc. The clinical manifestations are slowly developing joint pain, tenderness, stiffness, joint swelling, limited mobility and joint deformity. With the progress of aging in China, the number of patients with osteoarthritis increases year by year, and great economic burden and mental stress are brought to the society and families of the patients.
At present, some nonspecific medicines are mainly used for relieving clinical symptoms for treating osteoarthritis, and symptoms of arthritis patients are relieved by orally taking opioid analgesics and non-steroidal anti-inflammatory drugs, but the osteoarthritis cannot be fundamentally cured, and meanwhile, the medicines have more adverse reactions in the cardiovascular system and the gastrointestinal tract system and limit the application range of the medicines, so that research and development of novel medicines for treating the osteoarthritis are urgently needed.
Radix Zanthoxyli is dried root of Zanthoxylum nitidum (Roxb.) DC. The roots, stems and leaves of the plants are bitter and pungent in flavor and mild in nature. Has the main effects of promoting blood circulation, removing blood stasis, promoting qi circulation, relieving pain, dispelling pathogenic wind, dredging collaterals, removing toxic substance and relieving swelling, and is mainly used for treating traumatic injury, stomachache, toothache, rheumatalgia, venomous snake bite, external treatment of burn and scald, etc.
Stauntonia chinensis D.C. is dried stem and branch with leaves of Stauntonia chinensis D.of the family Akebia. Slightly bitter taste and mild nature; it enters liver and stomach meridians. Has the effects of dispelling wind, relieving pain, relaxing muscles and tendons and activating collaterals, and is clinically used for treating rheumatic arthralgia, lumbocrural pain, headache, toothache, dysmenorrhea and traumatic injury pain.
Caulis tinosporae sinensis, a kind of plant of the genus sinomenium of the family Menispermaceae, Tinospora sinensis (Lour.) Merr, has the effects of relaxing muscles and tendons, activating collaterals, dispelling pathogenic wind and relieving pain by using rattan as a medicine, and is mainly used for treating rheumatic arthralgia, sciatica, muscular spasm, difficulty in flexion and extension, lumbar muscle strain, traumatic injury and the like.
The caulis Bauhiniae includes Entada phaseoloides (L.) Merr. or caulis Bauhinia championii (Benth.) Benth. of Entada phaseoloides (L.) or Entada phaseoloides (L.) of Leguminosae. The plants are evergreen climbing nature vines and are 2-7 meters high. Has effects in dispelling pathogenic wind, removing dampness, promoting blood circulation, dispelling blood stasis, and relieving pain. Can be used for treating rheumatalgia, lumbago, leg pain, traumatic injury, and numbness of limbs.
The radix Clematidis is dried root and rhizome of Clematis chinensis Osbeck, Clematis hexapetala pall or Clematis manshurica Rupr of Ranunculaceae. Can dispel wind-damp and dredge channels and collaterals. Can be used for treating rheumatalgia, numbness of limbs, spasm of tendons and vessels, and difficulty in flexion and extension. Fresh plants can be used for treating acute tonsillitis and pharyngolaryngitis; can be used for treating filariasis and toothache. In modern clinical practice, new application of the traditional Chinese medicine is continuously discovered, such as treatment of gallstone, calcaneal spur, heel pain, esophageal cancer and the like.
The chicken bone incense is Croton crassifolius Geisel (C.chinensis Benth.) of Croton genus of Euphorbiaceae family, and is used as root medicine. Has effects of activating qi-flowing, promoting blood circulation, dispelling pathogenic wind, removing dampness, and relieving swelling and pain, and can be used for treating gastralgia, rheumatalgia, lumbago, skelalgia, abdominal pain, hernia pain, dysmenorrhea, swelling and pain of throat, traumatic injury, and snake and insect bite.
In the prior art, no report is provided for the application of compound rheumatism medicament obtained by combining radix zanthoxyli, stauntonvine, caulis tinosporae, climbing entada, radix clematidis and chicken bone essence in osteoarthritis.
Disclosure of Invention
The invention aims to provide a new application of radix zanthoxyli, stauntonvine, caulis tinosporae, climbing entada herb, radix clematidis and chicken bone incense in treating osteoarthritis after compounding in the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that: the application of compound rheumatism medicament in preparing medicament for treating osteoarthritis is disclosed, wherein the compound rheumatism medicament comprises the following medicinal materials in parts by weight: 300-1200 parts of zanthoxylum nitidum, 300-1200 parts of stauntonvine, 200-800 parts of tinospora sinensis, 200-800 parts of climbing entada, 100-500 parts of radix clematidis and 100-500 parts of chicken bone flavor.
As a preferred embodiment of the application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis, the compound rheumatism medicament comprises the following medicinal materials in parts by weight: 500-1000 parts of radix zanthoxyli, 500-1000 parts of stauntonvine, 300-700 parts of tinospora sinensis, 300-700 parts of climbing entada, 200-400 parts of radix clematidis and 200-400 parts of chicken bone flavor.
As a preferred embodiment of the application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis, the mass ratio of the radix zanthoxyli to the stauntonvine is 1: 1.
As a preferred embodiment of the application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis, the mass ratio of the tinospora sinensis stem to the climbing entada is 1: 1.
As a preferred embodiment of the application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis, the mass ratio of clematis root to chicken bone is 1: 1.
As a preferred embodiment of the application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis, the compound rheumatism medicament comprises the following medicinal materials in parts by weight: 750 parts of radix zanthoxyli, 750 parts of stauntonvine, 500 parts of tinospora sinensis, 500 parts of climbing entada, 250 parts of radix clematidis and 250 parts of chicken bone flavor.
As a preferred embodiment of the application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis, the compound rheumatism medicament comprises the following medicinal materials in parts by weight: 937.5 parts of shinyleaf pricklyash root, 937.5 parts of stauntonvine, 625 parts of tinospora sinensis, 625 parts of climbing entada, 312.5 parts of clematis root and 312.5 parts of chicken bone.
As a preferred embodiment of the application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis, the compound rheumatism medicament comprises the following medicinal materials in parts by weight: 800 parts of shinyleaf pricklyash root, 800 parts of wild papaya, 700 parts of tinospora sinensis, 700 parts of climbing entada, 300 parts of clematis root and 300 parts of chicken bone essence.
As a preferred embodiment of the application of the compound Fengshining in the preparation of the medicine for treating osteoarthritis, the medicine is added with extracts obtained by extracting all medicinal materials in the compound Fengshining, and the mass percentage of the compound Fengshining in the medicine is 30-95%.
As a preferred embodiment of the application of the compound Fengshining in the preparation of the medicine for treating osteoarthritis, the dosage form of the medicine is an oral solid preparation. As a more preferable embodiment of the application of the compound Fengshining in the preparation of the medicine for treating osteoarthritis, the dosage form of the medicine is tablets, capsules, granules, dripping pills or soft capsules.
The inventor of the application finds that after the radix zanthoxyli, the stauntonvine, the tinospora sinensis, the climbing entada herb, the radix clematidis and the chicken bone incense are compounded according to a specific proportion, the composition has a good effect in treating the osteoarthritis, and provides a new medicine selection for treating the osteoarthritis.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example 1
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 300 parts of shinyleaf pricklyash root, 300 parts of stauntonvine, 800 parts of tinospora sinensis, 800 parts of climbing entada, 100 parts of clematis root and 100 parts of chicken bone essence.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain a compound feng shi ning extract, and then the compound feng shi ning extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, dripping pills or soft capsules.
Example 2
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 750 parts of radix zanthoxyli, 750 parts of stauntonvine, 500 parts of tinospora sinensis, 500 parts of climbing entada, 250 parts of radix clematidis and 250 parts of chicken bone flavor.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain an extract, and then the extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, pills or soft capsules.
Example 3
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 1000 parts of radix zanthoxyli, 1000 parts of stauntonvine, 600 parts of tinospora sinensis, 600 parts of climbing entada, 200 parts of radix clematidis and 200 parts of chicken bone flavor.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain an extract, and then the extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, pills or soft capsules.
Example 4
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 937.5 parts of shinyleaf pricklyash root, 937.5 parts of stauntonvine, 625 parts of tinospora sinensis, 625 parts of climbing entada, 312.5 parts of clematis root and 312.5 parts of chicken bone.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain an extract, and then the extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, pills or soft capsules.
Example 5
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 500 parts of radix zanthoxyli, 500 parts of stauntonvine, 300 parts of tinospora sinensis, 300 parts of climbing entada, 400 parts of radix clematidis and 400 parts of chicken bone flavor.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain an extract, and then the extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, pills or soft capsules.
Example 6
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 800 parts of shinyleaf pricklyash root, 800 parts of wild papaya, 700 parts of tinospora sinensis, 700 parts of climbing entada, 300 parts of clematis root and 300 parts of chicken bone essence.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain an extract, and then the extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, pills or soft capsules.
Example 7
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 1200 parts of shinyleaf pricklyash root, 1200 parts of stauntonvine, 200 parts of tinospora sinensis, 200 parts of climbing entada, 500 parts of clematis root and 500 parts of chicken bone essence.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain an extract, and then the extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, pills or soft capsules.
Example 8
In an embodiment of an application of the compound feng shi ning in preparing a medicine for treating osteoarthritis, the compound feng shi ning comprises the following medicinal materials in parts by weight: 900 parts of shinyleaf pricklyash root, 900 parts of stauntonvine, 550 parts of tinospora sinensis, 550 parts of climbing entada, 450 parts of clematis root and 450 parts of chicken bone incense.
In this embodiment, each of the herbs in the compound feng shi ning is extracted to obtain an extract, and then the extract is combined with a pharmaceutically acceptable carrier to prepare an oral solid preparation, including but not limited to tablets, capsules, granules, pills or soft capsules.
Example 9
The effect test of the compound rheumatism preparation for treating osteoarthritis
Preparation of osteoarthritis model
SPF grade SD rats aged 12-14 weeks and weighing 220 + -30 g were anesthetized by intraperitoneal injection of 6% chloral hydrate (0.5mL/100g body weight). The electric shaver eliminates the hair of the right hind limb knee joint, the knee joint is disinfected by 75 percent of disinfection alcohol conventionally, and the joint is injected with 30 mu L of 50g/L sodium iodoacetate (passing through patellar ligament). The normal group is treated with physiological saline with the same amount, 2-3 normal groups and model groups are randomly selected after 2 weeks of modeling, the knee joint part is examined by nuclear magnetic resonance, and the joint capsule is cut at about 1cm above and below the femur and the tibia of the knee joint for general observation; performing HE, toluidine blue and immunohistochemical staining on the articular cartilage tissue; the model rat shows that one or more indexes of joint injection site swelling, inflammation, joint effusion, HE staining cell arrangement disorder, damp line blurring, toluidine blue light staining or losing staining, I type collagen expression or not and the like occur.
The test is divided into a normal control group, a model group and a test group, the normal control group adopts normal SPF SD rats, the model group adopts the osteoarthritis rat model prepared by the preparation method, the rats of the test group adopt the osteoarthritis rat model prepared by the preparation method, the test group is divided into the test group 1-8, 20 rats in each group and the rats of the test group 1-8 are subjected to gastric lavage for 4 weeks, and the drugs are respectively the drugs (2.5g crude drug kg) prepared in the above examples 1-8 (2.5g crude drug kg)-1·d-1Body weight), the normal control group and the model group were administered with an equal amount of physiological saline for intragastric administration. After 4 weeks, after fasting for 12 hours after the last administration, the condition of each group of rats was observed, specifically, the knee joint part was dissected, the damaged cartilage repair effect was observed, and the number of rats having a repair effect on the damaged cartilage in each group was counted, and the statistical results are shown in table 1.
Table 1 number of rats having repairing effect on damaged cartilage in each group
| Group of | Total number of rats | Number of rats with damaged cartilage repair | Rate of repair of damaged cartilage |
| Normal group | 20 | Cartilage injury | Cartilage injury |
| Model set | 20 | 0 | 0 |
| Test group 1 | 20 | 11 | 55％ |
| Test group 2 | 20 | 18 | 90％ |
| Test group 3 | 20 | 19 | 95％ |
| Test group 4 | 20 | 20 | 100％ |
| Test group 5 | 20 | 13 | 65％ |
| Test group 6 | 20 | 17 | 85％ |
| Test group 7 | 20 | 15 | 75％ |
| Test group 8 | 20 | 14 | 70％ |
As can be seen from the results in table 1, the damaged cartilage of the rats in the test group is effectively repaired compared with the cartilage of the rats in the model group, and particularly, the repair rate of the cartilage of the rats in the test groups 2, 3, 4 and 6 is higher, so that the compound rheumatism medicine preparation provided by the invention has the effect of treating osteoarthritis.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. The application of the compound rheumatism medicament in preparing the medicament for treating osteoarthritis is characterized in that the compound rheumatism medicament comprises the following medicinal materials in parts by weight: 300-1200 parts of zanthoxylum nitidum, 300-1200 parts of stauntonvine, 200-800 parts of tinospora sinensis, 200-800 parts of climbing entada, 100-500 parts of radix clematidis and 100-500 parts of chicken bone flavor.
2. The use of the compound feng shi ning as claimed in claim 1 in preparing a medicament for treating osteoarthritis is characterized in that the compound feng shi ning comprises the following herbs (by weight portion): 500-1000 parts of radix zanthoxyli, 500-1000 parts of stauntonvine, 300-700 parts of tinospora sinensis, 300-700 parts of climbing entada, 200-400 parts of radix clematidis and 200-400 parts of chicken bone flavor.
3. The use of the compound feng shi ning as claimed in claim 1 in preparing a medicament for treating osteoarthritis, wherein the mass ratio of radix zanthoxyli to stauntonvine is 1: 1.
4. The use of the compound feng shi ning as claimed in claim 1 in preparing a medicament for treating osteoarthritis, wherein the mass ratio of caulis tinosporae sinensis to caulis perllae, is 1: 1.
5. The use of the compound feng shi ning as claimed in claim 1 in preparing a medicament for treating osteoarthritis, wherein the mass ratio of clematis root to chicken bone essence is 1: 1.
6. The use of the compound feng shi ning as claimed in claim 1 in preparing medicine for treating osteoarthritis is characterized in that the compound feng shi ning comprises the following herbs (by weight portion): 750 parts of radix zanthoxyli, 750 parts of stauntonvine, 500 parts of tinospora sinensis, 500 parts of climbing entada, 250 parts of radix clematidis and 250 parts of chicken bone flavor.
7. The use of the compound feng shi ning as claimed in claim 1 in preparing medicine for treating osteoarthritis is characterized in that the compound feng shi ning comprises the following herbs (by weight portion): 937.5 parts of shinyleaf pricklyash root, 937.5 parts of stauntonvine, 625 parts of tinospora sinensis, 625 parts of climbing entada, 312.5 parts of clematis root and 312.5 parts of chicken bone.
8. The use of the compound feng shi ning as claimed in claim 1 in preparing medicine for treating osteoarthritis is characterized in that the compound feng shi ning comprises the following herbs (by weight portion): 800 parts of shinyleaf pricklyash root, 800 parts of wild papaya, 700 parts of tinospora sinensis, 700 parts of climbing entada, 300 parts of clematis root and 300 parts of chicken bone essence.
9. The use of the compound feng shi ning as claimed in any one of claims 1 to 8 in the preparation of a medicament for the treatment of osteoarthritis, wherein the dosage form of the medicament is an oral solid preparation.
10. The use of the compound feng shi ning as claimed in claim 9 in preparing a medicament for treating osteoarthritis, wherein the dosage form of the medicament is tablet, capsule, granule, dripping pill or soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011316500.8A CN112316020A (en) | 2020-11-19 | 2020-11-19 | Application of compound Fengshining preparation in treating osteoarthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011316500.8A CN112316020A (en) | 2020-11-19 | 2020-11-19 | Application of compound Fengshining preparation in treating osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112316020A true CN112316020A (en) | 2021-02-05 |
Family
ID=74320981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011316500.8A Pending CN112316020A (en) | 2020-11-19 | 2020-11-19 | Application of compound Fengshining preparation in treating osteoarthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112316020A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698713A (en) * | 2005-05-09 | 2005-11-23 | 叶耀良 | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof |
| CN107468799A (en) * | 2017-09-29 | 2017-12-15 | 广东罗浮山国药股份有限公司 | A kind of application of Chinese medicine composition in the medicine for preparing treatment disc herniation |
-
2020
- 2020-11-19 CN CN202011316500.8A patent/CN112316020A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698713A (en) * | 2005-05-09 | 2005-11-23 | 叶耀良 | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof |
| CN107468799A (en) * | 2017-09-29 | 2017-12-15 | 广东罗浮山国药股份有限公司 | A kind of application of Chinese medicine composition in the medicine for preparing treatment disc herniation |
Non-Patent Citations (1)
| Title |
|---|
| 姚文山主编: "《国家基本药物临床应用指南》", 28 February 2019, 天津科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN111529579A (en) | A Chinese medicinal composition for relieving hangover and treating alcoholic liver | |
| WO2021042275A1 (en) | Traditional chinese medicine composition for treating osteoarthritis | |
| CN112316020A (en) | Application of compound Fengshining preparation in treating osteoarthritis | |
| CN108939058A (en) | A kind of Chinese materia medica preparation and preparation method of promoting blood circulation and stopping pain | |
| KR100472408B1 (en) | Method For Preparing Composition For Treating Osteoporosis | |
| CN103690583A (en) | Medicinal liquor, and preparation method and application thereof | |
| CN107080796A (en) | A kind of Chinese medicine preparation for being used to treat Osteoarthritis | |
| CN113181258A (en) | A Chinese medicinal composition for treating menoxenia, dysmenorrhea, and amenorrhea | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN104524080A (en) | Traditional Chinese medicine preparation for treating injuries from falls, fractures, contusions and strains and preparation method | |
| CN104547489A (en) | Use of traditional Chinese medicine composition in preparation of medicine for treating comminuted fracture | |
| CN116763834B (en) | Traditional Chinese medicine composition and preparation for treating arthralgia as well as preparation method and application of traditional Chinese medicine composition and preparation | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN114588233B (en) | Composition for treating acute gout | |
| CN108310163A (en) | A kind of dispelling wind-evil and wetness-evil blood-activating Chinese medicine preparation and preparation method thereof | |
| CN109157635B (en) | Honeysuckle stem compound with anti-depression effect and preparation method and application thereof | |
| CN105770214A (en) | Traditional Chinese medicine preparation for treating ankle fracture and preparing method thereof | |
| CN105125988A (en) | Traditional Chinese medicinal preparation for treating thromboangiitis obliterans and preparation method of traditional Chinese medicinal preparation | |
| CN105663850A (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| Lekamge et al. | A review on effectiveness of selected herbal paste in the management of Rheumatoid Arthritis (Āmavāta) | |
| CN110393780A (en) | Chinese medicine composition, external preparation and its preparation method and application | |
| CN111249367A (en) | A Chinese medicinal preparation for treating osteoporosis, osteonecrosis, and bone generation and promoting blood circulation, and its preparation method | |
| CN111789907A (en) | Traditional Chinese medicine composition and application thereof | |
| CN110151884A (en) | A kind of Chinese materia medica preparation of blood circulation and channel invigorating and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210205 |
|
| RJ01 | Rejection of invention patent application after publication |